3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
5
Phase 2
4
Phase 1/2
3
Phase 1
3
Status
Active not recruiting
3
Recruiting
2
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Carcinoma, Renal Cell
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Kidney Neoplasms
1
Interventions
pembrolizumab
70
Nivolumab
36
Cyclophosphamide
34
Carboplatin
28
Dexamethasone
23
Specimen Handling
22
Paclitaxel
22
Lenalidomide
22
durvalumab
20
venetoclax
19
Radiotherapy
19
Gemcitabine
19
Magnetic Resonance Spectroscopy
18
Doxorubicin
17
Rituximab
16
fludarabine
15
Ipilimumab
15
Bevacizumab
15
Cisplatin
14
Biopsy
14
atezolizumab
13
Etoposide
13
Vincristine
12
Pemetrexed
12
Azacitidine
12
belantamab mafodotin
11
Docetaxel
11
Calcium Dobesilate
11
olaparib
10
Oxaliplatin
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 1/2
×
Active not recruiting
×
belzutifan
×
Clear all
NCT04626479
2026-05-18
MK-3475-03A
Merck Sharp & Dohme LLC
Phase 1/2
Active not recruiting
400 enrolled
NCT04626518
2026-05-06
KEYMAKER-U03
Merck Sharp & Dohme LLC
Phase 1/2
Active not recruiting
370 enrolled
NCT05468697
2026-01-23
MK-6482-024
Merck Sharp & Dohme LLC
Phase 1/2
Active not recruiting
60 enrolled